Gout Therapeutic Market is expected to grow at a CAGR of 15.5% during the forecast period and market is expected to reach US$ 12 Bn. by 2029. Gout is a form of inflammatory arthritis characterized by recurrent attacks of a red, tender, hot, and swollen joint. Pain typically comes on rapidly, reaching maximal intensity in less than 12 hours. Gout is due to persistently elevated levels of uric acid in the blood. This occurs from a combination of diet, other health problems, and genetic factors.To know about the Research Methodology :- Request Free Sample Report
Gout Therapeutic Market key segmentation
The urate lowering agents drug type is projected to grow at a faster rate among all the covered drug types. These agents are characterized majorly by the existence of xanthine oxidase inhibitor and uricosuric agents. Introduction of various drugs and growing preference towards adoption of this treatment is also expected to drive the growth in this industry. The online pharmacy segment is likely to expand at a rapid pace during the forecast period. Increase in the number of players by online pharmacy segment and acceptance of several gout therapeutics as over-the-counter drugs in the medical therapy to fulfill the rising demands of health care market are projected to boost the online pharmacy segment. Non-steroidal anti-inflammatory drugs (NSAIDs) was observed to be the dominant drug type in this market during 2018. Its cost effectiveness as compared to other drugs and easy availability in the market is another factor supporting the growth of this drug class during the forecast period.Drivers and Restrains
High share hold by the hospitals pharmacy segment is attributed to the increase in geriatric population with moderate to severe gout arthritis requiring hospital pharmacy to purchase drugs is considered to be the prominent factor fueling the market. Rising preference for combination therapies due to benefits such as speeding up the treatment process, reduction in side effects are also another factors enhancing the market growth. The incidence of gout has increased to a great extent in the past two decades. Stringent regulations and patent expiry of various blockbuster drugs are key restraints for the global Gout disease treatment market. Increasing mergers and collaborations between major companies and rapid product launches are major factors boosting the global Gout disease treatment market. Higher penetration of urate lowering drugs, as compared to biologics, into the gout therapeutics market for the treatment of people suffering from chronic or acute gout diseases propel the urate-lowering drugs segment. Increased adoption of biologics, R&D on regenerative medicines and technological advancements in imaging modalities improving the gout understanding and clinical applications ultimately driving the global gout therapeutic market. Lifestyle factors such as increasing smoking prevalence & alcohol consumption and stressed lifestyle is likely to boost the incidence of gout over the period, 2022-2029.Regional Analysis
North America held highest share of global gout therapeutic market 2018. High prevalence of gout owing to lifestyle issues such as high alcohol intake, obesity, and smoking resulting in the inflammatory disorder responsible for increase growth rate. Europe is considered to be the second-largest and highly attractive market for gout therapeutics. The gout therapeutics market in the region is expected to expand at a high CAGR during the forecast period, Attributed to these factors along with the adoption of innovative treatments and increased understanding about arthritic conditions, the market in Europe region is observed to be the dominant market during forecast period. The gout therapeutics market in the U.K. is likely to expand at a rapid pace during the forecast period. The country is projected to retain its share of the gout therapeutics market from 2022 to 2029. The objective of the report is to present comprehensive analysis of Global Gout Therapeutic Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding Global Gout Therapeutic Market dynamics, structure by analyzing the market segments, and project the Global Gout Therapeutic Market size. Clear representation of competitive analysis of key players by Gout Therapeutic Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Gout Therapeutic Market make the report investor’s guide.Gout Therapeutic Market Scope: Inquire before buying
Global Gout Therapeutic Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 4.37 Bn. Forecast Period 2023 to 2029 CAGR: 15.5% Market Size in 2029: US $ 12 Bn. Segments Covered: by drug type NSAIDs Corticosteroids Colchicine Urate-lowering agents by distribution channel Hospital pharmacies Retail pharmacies Online pharmacies by disease type Chronic Acute Gout Therapeutic Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Gout Therapeutic Market Key players are:
1. AstraZeneca, 2. Horizon Pharma plc, 3. Takeda Pharmaceutical Company Limited, 4. GlaxoSmithKline plc, 5. Novartis AG, 6. Merck & Co. Inc., 7. Teijin Pharma Limited, 8. Regeneron Pharmaceuticals, Inc., 9. Ironwood Pharmaceuticals, Inc., 10.JW Pharmaceutical, 11.Selecta Biosciences, Inc., 12.Grunenthal Group. 13.Boehringer Ingelheim 14.Alder Biopharmaceuticals 15.Eli Lilly 16.Antares Pharma 17.KaloBios Pharmaceuticals 18.Astellas Pharma 19.Can-Fite BioPharma 20.Ironwood Pharmaceuticals Frequently Asked Questions: 1. Which region has the largest share in Gout Therapeutic Market? Ans: North America region held the highest share in 2022. 2. What is the growth rate of Global Gout Therapeutic Market? Ans: The Global Gout Therapeutic Market is growing at a CAGR of 15.5% during forecasting period 2023-2029. 3. What is scope of the Global Gout Therapeutic market report? Ans: Global Gout Therapeutic Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Gout Therapeutic market? Ans: The important key players in the Global Gout Therapeutic Market are – AstraZeneca,, Horizon Pharma plc,, Takeda Pharmaceutical Company Limited,, GlaxoSmithKline plc,, Novartis AG,, Merck & Co. Inc.,, Teijin Pharma Limited,, Regeneron Pharmaceuticals, Inc.,, Ironwood Pharmaceuticals, Inc.,, JW Pharmaceutical,, Selecta Biosciences, Inc.,, Grunenthal Group., Boehringer Ingelheim, Alder Biopharmaceuticals, Eli Lilly, Antares Pharma, KaloBios Pharmaceuticals, Astellas Pharma, Can-Fite BioPharma, and Ironwood Pharmaceuticals 5. What is the study period of this market? Ans: The Global Gout Therapeutic Market is studied from 2022 to 2029.
Global Gout Therapeutic Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Gout Therapeutic Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Gout Therapeutic Market Analysis and Forecast 6.1. Global Gout Therapeutic Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Gout Therapeutic Market Analysis and Forecast, by Drug type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Gout Therapeutic Market Value Share Analysis, by Drug type 7.4. Global Gout Therapeutic Market Size (US$ Bn) Forecast, by Drug type 7.5. Global Gout Therapeutic Market Analysis, by Drug type 7.6. Global Gout Therapeutic Market Attractiveness Analysis, by Drug type 8. Global Gout Therapeutic Market Analysis and Forecast, by Disease 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Gout Therapeutic Market Value Share Analysis, by Disease 8.4. Global Gout Therapeutic Market Size (US$ Bn) Forecast, by Disease 8.5. Global Gout Therapeutic Market Analysis, by Disease 8.6. Global Gout Therapeutic Market Attractiveness Analysis, by Disease 9. Global Gout Therapeutic Market Analysis and Forecast, by Distribution channel 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Gout Therapeutic Market Value Share Analysis, by Distribution channel 9.4. Global Gout Therapeutic Market Size (US$ Bn) Forecast, by Distribution channel 9.5. Global Gout Therapeutic Market Analysis, by Distribution channel 9.6. Global Gout Therapeutic Market Attractiveness Analysis, by Distribution channel 10. Global Gout Therapeutic Market Analysis, by Region 10.1. Global Gout Therapeutic Market Value Share Analysis, by Region 10.2. Global Gout Therapeutic Market Size (US$ Bn) Forecast, by Region 10.3. Global Gout Therapeutic Market Attractiveness Analysis, by Region 11. North America Gout Therapeutic Market Analysis 11.1. Key Findings 11.2. North America Gout Therapeutic Market Overview 11.3. North America Gout Therapeutic Market Value Share Analysis, by Drug type 11.4. North America Gout Therapeutic Market Forecast, by Drug type 11.4.1. NSAIDs 11.4.2. Corticosteroids 11.4.3. Colchicine 11.4.4. Urate-lowering agents 11.5. North America Gout Therapeutic Market Value Share Analysis, by Disease 11.6. North America Gout Therapeutic Market Forecast, by Disease 11.6.1. Chronic 11.6.2. Acute 11.7. North America Gout Therapeutic Market Value Share Analysis, by Distribution channel 11.8. North America Gout Therapeutic Market Forecast, by Distribution channel 11.8.1. Hospital pharmacies 11.8.2. Retail pharmacies 11.8.3. Online pharmacies 11.9. North America Gout Therapeutic Market Value Share Analysis, by Country 11.10. North America Gout Therapeutic Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Gout Therapeutic Market Analysis, by Country 11.12. U.S. Gout Therapeutic Market Forecast, by Drug type 11.12.1. NSAIDs 11.12.2. Corticosteroids 11.12.3. Colchicine 11.12.4. Urate-lowering agents 11.13. U.S. Gout Therapeutic Market Forecast, by Disease 11.13.1. Chronic 11.13.2. Acute 11.14. U.S. Gout Therapeutic Market Forecast, by Distribution channel 11.14.1. Hospital pharmacies 11.14.2. Retail pharmacies 11.14.3. Online pharmacies 11.15. Canada Gout Therapeutic Market Forecast, by Drug type 11.15.1. NSAIDs 11.15.2. Corticosteroids 11.15.3. Colchicine 11.15.4. Urate-lowering agents 11.16. Steel Canada Gout Therapeutic Market Forecast, by Disease 11.16.1. Chronic 11.16.2. Acute 11.17. Canada Gout Therapeutic Market Forecast, by Distribution channel 11.17.1. Hospital pharmacies 11.17.2. Retail pharmacies 11.17.3. Online pharmacies 11.18. North America Gout Therapeutic Market Attractiveness Analysis 11.18.1. By Drug type 11.18.2. By Disease 11.18.3. By Distribution channel 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Gout Therapeutic Market Analysis 12.1. Key Findings 12.2. Europe Gout Therapeutic Market Overview 12.3. Europe Gout Therapeutic Market Value Share Analysis, by Drug type 12.4. Europe Gout Therapeutic Market Forecast, by Drug type 12.4.1. NSAIDs 12.4.2. Corticosteroids 12.4.3. Colchicine 12.4.4. Urate-lowering agents 12.5. Europe Gout Therapeutic Market Value Share Analysis, by Disease 12.6. Europe Gout Therapeutic Market Forecast, by Disease 12.6.1. Chronic 12.6.2. Acute 12.7. Europe Gout Therapeutic Market Value Share Analysis, by Distribution channel 12.8. Europe Gout Therapeutic Market Forecast, by Distribution channel 12.8.1. Hospital pharmacies 12.8.2. Retail pharmacies 12.8.3. Online pharmacies 12.9. Europe Gout Therapeutic Market Value Share Analysis, by Country 12.10. Europe Gout Therapeutic Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Gout Therapeutic Market Analysis, by Country 12.12. Germany Gout Therapeutic Market Forecast, by Drug type 12.12.1. NSAIDs 12.12.2. Corticosteroids 12.12.3. Colchicine 12.12.4. Urate-lowering agents 12.13. Germany Gout Therapeutic Market Forecast, by Disease 12.13.1. Chronic 12.13.2. Acute 12.14. Germany Gout Therapeutic Market Forecast, by Distribution channel 12.14.1. Hospital pharmacies 12.14.2. Retail pharmacies 12.14.3. Online pharmacies 12.15. U.K. Gout Therapeutic Market Forecast, by Drug type 12.15.1. NSAIDs 12.15.2. Corticosteroids 12.15.3. Colchicine 12.15.4. Urate-lowering agents 12.16. U.K. Gout Therapeutic Market Forecast, by Disease 12.16.1. Chronic 12.16.2. Acute 12.17. U.K. Gout Therapeutic Market Forecast, by Distribution channel 12.17.1. Hospital pharmacies 12.17.2. Retail pharmacies 12.17.3. Online pharmacies 12.18. France Gout Therapeutic Market Forecast, by Drug type 12.18.1. NSAIDs 12.18.2. Corticosteroids 12.18.3. Colchicine 12.18.4. Urate-lowering agents 12.19. France Gout Therapeutic Market Forecast, by Disease 12.19.1. Chronic 12.19.2. Acute 12.20. France Gout Therapeutic Market Forecast, by Distribution channel 12.20.1. Hospital pharmacies 12.20.2. Retail pharmacies 12.20.3. Online pharmacies 12.21. Italy Gout Therapeutic Market Forecast, by Drug type 12.21.1. NSAIDs 12.21.2. Corticosteroids 12.21.3. Colchicine 12.21.4. Urate-lowering agents 12.22. Italy Gout Therapeutic Market Forecast, by Disease 12.22.1. Chronic 12.22.2. Acute 12.23. Italy Gout Therapeutic Market Forecast, by Distribution channel 12.23.1. Hospital pharmacies 12.23.2. Retail pharmacies 12.23.3. Online pharmacies 12.24. Spain Gout Therapeutic Market Forecast, by Drug type 12.24.1. NSAIDs 12.24.2. Corticosteroids 12.24.3. Colchicine 12.24.4. Urate-lowering agents 12.25. Spain Gout Therapeutic Market Forecast, by Disease 12.25.1. Chronic 12.25.2. Acute 12.26. Spain Gout Therapeutic Market Forecast, by Distribution channel 12.26.1. Hospital pharmacies 12.26.2. Retail pharmacies 12.26.3. Online pharmacies 12.27. Rest of Europe Gout Therapeutic Market Forecast, by Drug type 12.27.1. NSAIDs 12.27.2. Corticosteroids 12.27.3. Colchicine 12.27.4. Urate-lowering agents 12.28. Rest of Europe Gout Therapeutic Market Forecast, by Disease 12.28.1. Chronic 12.28.2. Acute 12.29. Rest Of Europe Gout Therapeutic Market Forecast, by Distribution channel 12.29.1. Hospital pharmacies 12.29.2. Retail pharmacies 12.29.3. Online pharmacies 12.30. Europe Gout Therapeutic Market Attractiveness Analysis 12.30.1. By Drug type 12.30.2. By Disease 12.30.3. By Distribution channel 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Gout Therapeutic Market Analysis 13.1. Key Findings 13.2. Asia Pacific Gout Therapeutic Market Overview 13.3. Asia Pacific Gout Therapeutic Market Value Share Analysis, by Drug type 13.4. Asia Pacific Gout Therapeutic Market Forecast, by Drug type 13.4.1. NSAIDs 13.4.2. Corticosteroids 13.4.3. Colchicine 13.4.4. Urate-lowering agents 13.5. Asia Pacific Gout Therapeutic Market Value Share Analysis, by Disease 13.6. Asia Pacific Gout Therapeutic Market Forecast, by Disease 13.6.1. Chronic 13.6.2. Acute 13.7. Asia Pacific Gout Therapeutic Market Value Share Analysis, by Distribution channel 13.8. Asia Pacific Gout Therapeutic Market Forecast, by Distribution channel 13.8.1. Hospital pharmacies 13.8.2. Retail pharmacies 13.8.3. Online pharmacies 13.9. Asia Pacific Gout Therapeutic Market Value Share Analysis, by Country 13.10. Asia Pacific Gout Therapeutic Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Gout Therapeutic Market Analysis, by Country 13.12. China Gout Therapeutic Market Forecast, by Drug type 13.12.1. NSAIDs 13.12.2. Corticosteroids 13.12.3. Colchicine 13.12.4. Urate-lowering agents 13.13. China Gout Therapeutic Market Forecast, by Disease 13.13.1. Chronic 13.13.2. Acute 13.14. China Gout Therapeutic Market Forecast, by Distribution channel 13.14.1. Hospital pharmacies 13.14.2. Retail pharmacies 13.14.3. Online pharmacies 13.15. India Gout Therapeutic Market Forecast, by Drug type 13.15.1. NSAIDs 13.15.2. Corticosteroids 13.15.3. Colchicine 13.15.4. Urate-lowering agents 13.16. India Gout Therapeutic Market Forecast, by Disease 13.16.1. Chronic 13.16.2. Acute 13.17. India Gout Therapeutic Market Forecast, by Distribution channel 13.17.1. Hospital pharmacies 13.17.2. Retail pharmacies 13.17.3. Online pharmacies 13.18. Japan Gout Therapeutic Market Forecast, by Drug type 13.18.1. NSAIDs 13.18.2. Corticosteroids 13.18.3. Colchicine 13.18.4. Urate-lowering agents 13.19. Japan Gout Therapeutic Market Forecast, by Disease 13.19.1. Chronic 13.19.2. Acute 13.20. Japan Gout Therapeutic Market Forecast, by Distribution channel 13.20.1. Hospital pharmacies 13.20.2. Retail pharmacies 13.20.3. Online pharmacies 13.21. ASEAN Gout Therapeutic Market Forecast, by Drug type 13.21.1. NSAIDs 13.21.2. Corticosteroids 13.21.3. Colchicine 13.21.4. Urate-lowering agents 13.22. ASEAN Gout Therapeutic Market Forecast, by Disease 13.22.1. Chronic 13.22.2. Acute 13.23. ASEAN Gout Therapeutic Market Forecast, by Distribution channel 13.23.1. Hospital pharmacies 13.23.2. Retail pharmacies 13.23.3. Online pharmacies 13.24. Rest of Asia Pacific Gout Therapeutic Market Forecast, by Drug type 13.24.1. NSAIDs 13.24.2. Corticosteroids 13.24.3. Colchicine 13.24.4. Urate-lowering agents 13.25. Rest of Asia Pacific Gout Therapeutic Market Forecast, by Disease 13.25.1. Chronic 13.25.2. Acute 13.26. Rest of Asia Pacific Gout Therapeutic Market Forecast, by Distribution channel 13.26.1. Hospital pharmacies 13.26.2. Retail pharmacies 13.26.3. Online pharmacies 13.27. Asia Pacific Gout Therapeutic Market Attractiveness Analysis 13.27.1. By Drug type 13.27.2. By Disease 13.27.3. By Distribution channel 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Gout Therapeutic Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Gout Therapeutic Market Overview 14.3. Middle East & Africa Gout Therapeutic Market Value Share Analysis, by Drug type 14.4. Middle East & Africa Gout Therapeutic Market Forecast, by Drug type 14.4.1. NSAIDs 14.4.2. Corticosteroids 14.4.3. Colchicine 14.4.4. Urate-lowering agents 14.5. Middle East & Africa Gout Therapeutic Market Value Share Analysis, by Disease 14.6. Middle East & Africa Gout Therapeutic Market Forecast, by Disease 14.6.1. Chronic 14.6.2. Acute 14.7. Middle East & Africa Gout Therapeutic Market Value Share Analysis, by Distribution channel 14.8. Middle East & Africa Gout Therapeutic Market Forecast, by Distribution channel 14.8.1. Hospital pharmacies 14.8.2. Retail pharmacies 14.8.3. Online pharmacies 14.9. Middle East & Africa Gout Therapeutic Market Value Share Analysis, by Country 14.10. Middle East & Africa Gout Therapeutic Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Gout Therapeutic Market Analysis, by Country 14.12. GCC Gout Therapeutic Market Forecast, by Drug type 14.12.1. NSAIDs 14.12.2. Corticosteroids 14.12.3. Colchicine 14.12.4. Urate-lowering agents 14.13. GCC Gout Therapeutic Market Forecast, by Disease 14.13.1. Chronic 14.13.2. Acute 14.14. GCC Gout Therapeutic Market Forecast, by Distribution channel 14.14.1. Hospital pharmacies 14.14.2. Retail pharmacies 14.14.3. Online pharmacies 14.15. South Africa Gout Therapeutic Market Forecast, by Drug type 14.15.1. NSAIDs 14.15.2. Corticosteroids 14.15.3. Colchicine 14.15.4. Urate-lowering agents 14.16. South Africa Gout Therapeutic Market Forecast, by Disease 14.16.1. Chronic 14.16.2. Acute 14.17. South Africa Gout Therapeutic Market Forecast, by Distribution channel 14.17.1. Hospital pharmacies 14.17.2. Retail pharmacies 14.17.3. Online pharmacies 14.18. Rest of Middle East & Africa Gout Therapeutic Market Forecast, by Drug type 14.18.1. NSAIDs 14.18.2. Corticosteroids 14.18.3. Colchicine 14.18.4. Urate-lowering agents 14.19. Rest of Middle East & Africa Gout Therapeutic Market Forecast, by Disease 14.19.1. Chronic 14.19.2. Acute 14.20. Rest of Middle East & Africa Gout Therapeutic Market Forecast, by Distribution channel 14.20.1. Hospital pharmacies 14.20.2. Retail pharmacies 14.20.3. Online pharmacies 14.21. Middle East & Africa Gout Therapeutic Market Attractiveness Analysis 14.21.1. By Drug type 14.21.2. By Disease 14.21.3. By Distribution channel 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Gout Therapeutic Market Analysis 15.1. Key Findings 15.2. South America Gout Therapeutic Market Overview 15.3. South America Gout Therapeutic Market Value Share Analysis, by Drug type 15.4. South America Gout Therapeutic Market Forecast, by Drug type 15.4.1. NSAIDs 15.4.2. Corticosteroids 15.4.3. Colchicine 15.4.4. Urate-lowering agents 15.5. South America Gout Therapeutic Market Value Share Analysis, by Disease 15.6. South America Gout Therapeutic Market Forecast, by Disease 15.6.1. Chronic 15.6.2. Acute 15.7. South America Gout Therapeutic Market Value Share Analysis, by Distribution channel 15.8. South America Gout Therapeutic Market Forecast, by Distribution channel 15.8.1. Hospital pharmacies 15.8.2. Retail pharmacies 15.8.3. Online pharmacies 15.9. South America Gout Therapeutic Market Value Share Analysis, by Country 15.10. South America Gout Therapeutic Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Gout Therapeutic Market Analysis, by Country 15.12. Brazil Gout Therapeutic Market Forecast, by Drug type 15.12.1. NSAIDs 15.12.2. Corticosteroids 15.12.3. Colchicine 15.12.4. Urate-lowering agents 15.13. Brazil Gout Therapeutic Market Forecast, by Disease 15.13.1. Chronic 15.13.2. Acute 15.14. Brazil Gout Therapeutic Market Forecast, by Distribution channel 15.14.1. Hospital pharmacies 15.14.2. Retail pharmacies 15.14.3. Online pharmacies 15.15. Mexico Gout Therapeutic Market Forecast, by Drug type 15.15.1. NSAIDs 15.15.2. Corticosteroids 15.15.3. Colchicine 15.15.4. Urate-lowering agents 15.16. Mexico Gout Therapeutic Market Forecast, by Disease 15.16.1. Chronic 15.16.2. Acute 15.17. Mexico Gout Therapeutic Market Forecast, by Distribution channel 15.17.1. Hospital pharmacies 15.17.2. Retail pharmacies 15.17.3. Online pharmacies 15.18. Rest of South America Gout Therapeutic Market Forecast, by Drug type 15.18.1. NSAIDs 15.18.2. Corticosteroids 15.18.3. Colchicine 15.18.4. Urate-lowering agents 15.19. Rest of South America Gout Therapeutic Market Forecast, by Disease 15.19.1. Chronic 15.19.2. Acute 15.20. Rest of South America Gout Therapeutic Market Forecast, by Distribution channel 15.20.1. Hospital pharmacies 15.20.2. Retail pharmacies 15.20.3. Online pharmacies 15.21. South America Gout Therapeutic Market Attractiveness Analysis 15.21.1. By Drug type 15.21.2. By Disease 15.21.3. By Distribution channel 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Basware 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. AstraZeneca, 16.3.3. Horizon Pharma plc, 16.3.4. Takeda Pharmaceutical Company Limited, 16.3.5. GlaxoSmithKline plc, 16.3.6. Novartis AG, 16.3.7. Merck & Co. Inc., 16.3.8. Teijin Pharma Limited, 16.3.9. Regeneron Pharmaceuticals, Inc., 16.3.10. Ironwood Pharmaceuticals, Inc., 16.3.11. JW Pharmaceutical, 16.3.12. Selecta Biosciences, Inc., 16.3.13. Grunenthal Group 16.3.14. Boehringer Ingelheim 16.3.15. Alder Biopharmaceuticals 16.3.16. Eli Lilly 16.3.17. Antares Pharma 16.3.18. KaloBios Pharmaceuticals 16.3.19. Astellas Pharma 16.3.20. Can-Fite BioPharma 16.3.21. Ironwood Pharmaceuticals 17. Primary Key Insights